InspireMD Inc
XBER:II2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
InspireMD Inc
XBER:II2
|
IL |
|
Phillips 66
NYSE:PSX
|
US |
|
GR Engineering Services Ltd
ASX:GNG
|
AU |
|
Argan Inc
NYSE:AGX
|
US |
|
V
|
Vina San Pedro Tarapaca SA
SGO:VSPT
|
CL |
|
E
|
Exxon Mobil Corp
BMV:XOM
|
US |
|
A2B Australia Ltd
ASX:A2B
|
AU |
|
Priority Technology Holdings Inc
NASDAQ:PRTH
|
US |
|
Terns Pharmaceuticals Inc
NASDAQ:TERN
|
US |
|
I
|
Infinitt Healthcare Co Ltd
KOSDAQ:071200
|
KR |
|
H
|
Hutter & Schrantz Stahlbau AG
VSE:HST
|
AT |
|
T
|
Top Material Co Ltd
KOSDAQ:360070
|
KR |
Wall Street
Price Targets
II2 Price Targets Summary
InspireMD Inc
According to Wall Street analysts, the average 1-year price target for
II2
is 23.1 EUR
with a low forecast of 18.299 EUR and a high forecast of 28.536 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is II2's stock price target?
Price Target
23.1
EUR
According to Wall Street analysts, the average 1-year price target for
II2
is 23.1 EUR
with a low forecast of 18.299 EUR and a high forecast of 28.536 EUR.
What is InspireMD Inc's Revenue forecast?
Projected CAGR
58%
For the last 12 years the
compound annual growth rate for
InspireMD Inc's revenue is
3%.
The projected
CAGR
for the next 3 years is
58%.
